WB
H M
Endogenous
50
Rabbit IgG
#Q9BUZ4
9618
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg124 of human TRAF4 protein.
Background
TRAFs (TNF receptor-associated factors) are a family of multifunctional adaptor proteins that bind to surface receptors and recruit additional proteins to form multiprotein signaling complexes capable of promoting cellular responses (1-3). Members of the TRAF family share a common carboxy-terminal "TRAF domain", which mediates interactions with associated proteins; many also contain amino-terminal Zinc/RING finger motifs. The first TRAFs identified, TRAF1 and TRAF2, were found by virtue of their interactions with the cytoplasmic domain of TNF-receptor 2 (TNFRII) (4). The six known TRAFs (TRAF1-6) act as adaptor proteins for a wide range of cell surface receptors and participate in the regulation of cell survival, proliferation, differentiation, and stress responses.
TRAF4, also referred to as CART1 and MLN62, is a divergent member of the TRAF family with relatively weak binding to TNFR family members (5-7). Interactions have been observed between TRAF4 and the neurotrophin receptor p75-NGFR, lymphotoxin-β receptor, and GITR (8-10). While originally identified in metastatic breast carcinoma, TRAF4 has been shown to contribute to tumor growth and invasion in various cancers including breast, lung and colon (11-13). Expression of Traf4 is induced by the tumor suppressor p53 in response to DNA damage, and can promote apoptosis (14).TRAF4 has also been shown to play a critical role in TGF-β signaling, where it has been found to antagonize the E3 ligase Smurf, resulting in enhanced receptor stabilization driving breast cancer metastasis (15).
- Arch, R.H. et al. (1998) Genes Dev 12, 2821-30.
- Chung, J.Y. et al. (2002) J Cell Sci 115, 679-88.
- Bradley, J.R. and Pober, J.S. (2001) Oncogene 20, 6482-91.
- Rothe, M. et al. (1994) Cell 78, 681-92.
- Kawamata, S. et al. (1998) J Biol Chem 273, 5808-14.
- Régnier, C.H. et al. (1995) J Biol Chem 270, 25715-21.
- Bièche, I. et al. (1996) Cancer Res 56, 3886-90.
- Yang, K. et al. (2015) Int J Clin Exp Pathol 8, 1419-26.
- Camilleri-Broët, S. et al. (2007) Oncogene 26, 142-7.
- Li, W. et al. (2013) Cancer Res 73, 6938-50.
- Ye, X. et al. (1999) J Biol Chem 274, 30202-8.
- Esparza, E.M. and Arch, R.H. (2004) Cell Mol Life Sci 61, 3087-92.
- Krajewska, M. et al. (1998) Am J Pathol 152, 1549-61.
- Sax, J.K. and El-Deiry, W.S. (2003) J Biol Chem 278, 36435-44.
- Zhang, L. et al. (2013) Mol Cell 51, 559-72.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专